pharmaceuticals

pharmaceuticals Articles

In addition to rising hopes for a change in U.S. law removing marijuana from a list of dangerous drugs, a swarm of retail investors has been taking aim at pot stock short sellers. Here's how that's...
London-based Jazz Pharmaceuticals has agreed to pay $7.2 billion to acquire GW Pharmaceuticals, a maker of drugs derived from cannabis plants.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional...
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Prevail Therapeutics shares absolutely exploded on Tuesday morning after it was announced that the company would be acquired by Eli Lilly.
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.